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Key Learning points 
Antipsychotic medication is often prescribed to adults with intellectual disability and/or autism 
to manage behaviour that challenges despite little research evidence that antipsychotics are 
effective 
The STOMP campaign is aimed at reducing inappropriate prescribing of antipsychotic 
medication for people with ID and/or autism 
There is an absence of robust evidence on the most effective way to reduce or stop 
antipsychotic medication 
Withdrawing medication requires a multidisciplinary approach, consideration of co-morbidity 
and the involvement of patients and their carers 
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Introduction 
 
Intellectual disability (ID; also known as learning disability) is characterised by significant 
impairment of both cognitive functioning and adaptive behaviours, and an onset in early 
childhood. People with intellectual disability experience a different pattern of morbidity to the 
general population and die considerably younger than their counterparts without ID.1 
Autism is a neurodevelopmental disorder characterised by troubles with social interaction 
and communication, and by restricted and repetitive behaviour. In both conditions, complex 
mental and physical health problems, as well as social issues, are common and are 
associated with communication difficulties that can result in maladaptive behaviour patterns 
(often referred to as ‘behaviour that challenges’). Ideally, all people presenting with 
behaviour that challenges should be assessed by a specialist multidisciplinary team 
(comprising psychiatrists, psychologists, speech and language therapists, occupational 
therapists) to develop an understanding of the behaviour and an appropriate support plan 
with tailored treatment strategies and specialist follow-up.2 Non-pharmacological 
interventions for challenging behaviour, such as positive behaviour support or cognitive 
behaviour therapy, and manipulation of environmental triggers, are preferred to psychotropic 
medication. However antipsychotic medication is often prescribed to adults with ID and/or 
autism to manage behaviour that challenges in the absence of severe mental illness, despite 
there being little research evidence that antipsychotics are effective in this context.3 
 
Problems with antipsychotics  
 
There are complexities in prescribing, dispensing and administering psychotropic medication 
for adults with ID and/or autism, and a significant proportion will lack capacity to consent to 
treatment.4 There is widespread multi-morbidity and polypharmacy, increasing the potential 
for drug-disease and drug-drug interactions. In addition, people with ID and/or autism tend to 
be more sensitive to adverse drug effects and have atypical responses to drug treatment. A 
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national report that highlighted concerns related to overuse of psychotropic medication in 
people with ID and/or autism, was followed by data from population-based studies describing 
the scale of psychotropic prescribing in this group of people, a national guideline on 
assessment and management of behaviour that challenges,  a NHS quality improvement 
report on optimising use of medicines, and the national Stopping Overuse of Medication in 
People with Learning Disabilities and/or autism (STOMP) campaign.2,5-9. 
 
Targeting antipsychotic use 
 
The STOMP campaign is part of the NHS England ‘call to action’ aimed at reducing 
inappropriate psychotropic prescribing for people with ID and/or autism. Although it has 
achieved widespread publicity and support from professional and lay groups, the programme 
has been limited by a lack of evidence-based advice for clinicians, patients, and carers, on 
an approach to antipsychotic medication reduction. The National Institute for Health and 
Care Excellence (NICE) guideline on interventions for people with learning disabilities whose 
behaviour challenges, highlighted the importance of documenting a rationale for medication, 
how long the medication should be taken for and a strategy for reviewing and stopping 
medication.2 These resources have been highlighted in Box 1.  
 
However, there is little practical instruction about how best to achieve this. The clinical 
challenge is the safe and successful reduction of antipsychotic drugs used for behaviour that 
challenges, particularly in those who have been prescribed medication for extended periods 
of time. This sits within a broader approach of medication optimisation to maximise the 
benefit and minimise the harms of prescribed medication for the benefit of the individual. 
 
Evidence so far 
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The authors of a major systematic review (21 studies, 1027 participants) concluded that 
antipsychotics can be reduced or discontinued in a substantial proportion of adults with ID 
who use them for behaviour that challenges, although not always without adverse effects.10 
There were potential benefits in weight reduction, metabolic markers and cognitive function 
when antipsychotic drugs were withdrawn. In the 10 studies that reported success of 
medication reduction programmes, the proportion of participants who discontinued 
antipsychotics ranged from 4% to 74%, the proportion maintained on a reduced 
antipsychotic dose at follow-up was between 19% and 83%, and the proportion unsuccessful 
in attempts to reduce or discontinue antipsychotics was between 0% and 96%. However, the 
overall quality of evidence was poor and studies were prone to bias. Harms associated with 
medication reduction included worsening of behaviour and exposure (and deterioration) of 
previously undiagnosed mental illness. The review authors acknowledged that 
antipsychotics are likely to have a role as part of the management of some cases of 
behaviour that challenges in adults with ID, and concluded that there remains relatively little 
information to guide practice in reducing or discontinuing antipsychotic use.  
 
Despite significant attention, there has been little in the way of empirical evidence since this 
review. A randomised controlled trial funded by the UK National Institute for Health Research 
tested the outcome of a medication withdrawal programme for adults with ID and no 
diagnosis of psychosis who were prescribed risperidone for behaviour that challenges.11 
Participants were randomised to either their usual dose of antipsychotic or gradually 
reducing doses over a six-month period with placebo to maintain blinding. Recruitment was 
difficult and slow, largely as a result of practical issues in identifying and consenting suitable 
participants, and carer concerns regarding re-emergence of challenging behaviour with 
medication reduction. The trial’s organisers planned to recruit 310 participants but only 22 
were randomised and the study was under-powered to detect differences between groups. 
The authors noted that concerns about taking part were likely to have been exacerbated by 
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limited availability of alternative interventions to manage behaviour and that there is a need 
for focused support and alternative interventions in conjunction with medication reduction.  
 
A recent Dutch study aimed to identify determinants of successful and unsuccessful 
antipsychotic discontinuation attempts in people with ID who were prescribed these 
medications for behaviour that challenges.12 Eligible participants were those with ID over the 
age of 5 years, living in specialist accommodation who were prescribed antipsychotic 
medication for behaviour that challenges in the absence of severe mental illness. A 
reduction schedule of 12.5% of baseline dose every two weeks was chosen and was 
completed unblinded. The primary outcome was achievement of complete discontinuation at 
16 weeks. Changes in the Aberrant Behavior Checklist (ABC), a validated scale of behaviour 
that challenges, was a secondary outcome. Of 499 eligible people, 129 were recruited. 
Reasons for non-participation were clinician concern that discontinuation might increase 
challenging behaviours, and concurrent changes in “clients’ environment”. Of the 129 
participants, 61% had completely discontinued antipsychotics at 16 weeks, although 
subsequent re-prescribing reduced the figure to 46% at 28 weeks, and 40% at 40 weeks. 
Total ABC scores increased in almost half of participants with unsuccessful discontinuation 
at 16 weeks, highlighting the possible risks of embarking on a reduction programme. Autism, 
higher baseline dose of antipsychotic medication, and higher ABC scores were associated 
with a lower likelihood of complete discontinuation. Overall, 40% of participants with ID who 
had been judged by their responsible clinician to be eligible for a withdrawal trial of their 
long-term, off-label antipsychotic drug were able to discontinue over 4-7 months, with, on 
average, no behavioural worsening. However, selection bias limits the generalisability of 
these findings.  
 
As well as individual clinical factors, setting and staff characteristics also seem to strongly 
influence the ability to reduce of antipsychotic drugs. There is evidence to suggest that staff 
and environmental variables have a significant effect on success of antipsychotic reduction 
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attempts.13 Favourable environmental conditions and good support can increase the 
proportion of people in whom reduction attempts are successful. Such observations highlight 
the importance of informed commissioning decisions and building consensus with family and 
carers prior to initiating antipsychotic reduction.  
 
Practical issues 
 
The absence of robust evidence means that universal and precise instructions for reducing 
medication elude us, and a pragmatic and individualised approach to deprescribing 
antipsychotic medication used for behaviour that challenges is needed. We have argued for 
rational, rather than rationed, prescribing of psychotropic medications and an emphasis on 
medication optimisation, rather than total medication withdrawal.14 For some, this may mean 
reducing medication to a minimally effective dose, without reaching complete 
discontinuation.  
 
A medication optimisation approach requires shared decision-making and consideration of 
individual and contextual factors. Understanding an individual and their concerns should 
form the starting point of a discussion about medication use. Obtaining a chronology to 
identify when and why antipsychotic medication was prescribed is recommended, although 
can be difficult in practice when a drug may have been prescribed for many years and 
people have moved between services and care providers. 
 
The possible advantages and disadvantages of medication continuation or reduction should 
be explained making use of adapted communication techniques and materials, as 
necessary, and including family members and paid carers where appropriate. Written 
resources can be provided to aid decision making. Where an individual lacks capacity to 
make decisions about medication, a best interest decision should be made in line with the 
provisions of the Mental Capacity Act. It is important to communicate and record discussions 
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and decisions clearly, including any challenges or barriers, particularly social and 
environmental ones, which prevent the partial or full reduction of antipsychotic medication. 
The commitment from all parties must be recognised.  
 
Provision of alternative approaches to managing behaviour that challenges is important to 
instil confidence in pursuing medication change and to mitigate any behavioural worsening 
during dose reductions (see table 1 and pathway 1). This includes an up-to-date and feasible 
behaviour support plan, with contingency planning and options for crisis management.  
The optimum rate of medication reduction is not defined and should be determined 
individually. There is little information on how commonplace or successful it is to add an 
alternative psychotropic drug during the course of antipsychotic reduction. Although this may 
overcome the psychological barrier of being without medication, we must remember that no 
psychotropic class has been shown to improve behaviour that challenges in the absence of 
mental illness, and substituting one medication class for another may merely prolong 
inappropriate prescribing.  
 
It is good practice to ensure baseline physical investigations and blood tests are completed 
and records on physical health updated prior to medication change. Ensuring a monitoring 
framework is in place is important and could be negotiated between primary and secondary 
care.15 This might require suitable education and discussion with primary care 
stakeholders.16 
 
Where cases have proved to be challenging ‘learning from experience’ meetings within 
continued professional development networks might help to generate new ideas and share 
good practice.   
 
The major pitfalls to be mindful of in reducing antipsychotic medication used for behaviour 
that challenges include:  
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1. Unmasking a hitherto unrecognised mental illness  
To minimise this risk it is important that all relevant stakeholders understand markers 
of relapse and are encouraged and supported to report any changes noticed during 
reduction. It might help to agree on a slow titration schedule giving 6 to 12 weeks 
gaps between each dose reduction. For complex cases, consideration should be 
given to assessing mental state and wellbeing clinically and using structured tools 
such as the mini-PAS-ADD (Psychiatric Assessment Schedule for Adult with 
Developmental Disability) and HoNOS-LD (Health of the Nation Outcome Scales for 
People with Learning Disabilities) at baseline and at each stage of medication 
reduction.  
2. Misinterpreting concurrent physical, psychological or social changes 
Confounders in the form of physical health conditions (e.g. pain, acute infection), 
psychological issues (e.g. new stress, bereavement) or social issues (e.g. carer 
change, changes in support environment) can impact an individual’s mental state. 
This might lead to diagnostic overshadowing and incorrectly attributing a change to 
the medication reduction. It is important to recognise with the individual’s broader 
needs and, if necessary, temporarily halt or slow the rate of antipsychotic withdrawal.  
3. Inappropriate medication use 
In some cases, medication is used as a substitute for a social or psychological 
intervention. A full medication review should identify inappropriate use and provide 
justification and impetus for the withdrawal attempt. This clarity should ensure the 
correct framework of support exists to facilitate withdrawal.  
4. Multimorbidity leading to challenging behaviour  
There needs to be a good understanding of co-morbidities, particularly neuro-
developmental conditions (e.g. autism and attention deficit hyperactivity disorder) and 
genetic conditions that are associated with behaviour that challenges. Epilepsy, 
present in roughly 25% of people with ID and 33% of those with autism, and/or its 
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treatment can be associated with behaviour that challenges. Specialist assessment 
may be required if there is uncertainty in this area.  
 
Future developments 
 
Other interventions that have been suggested to aid medication withdrawal include the use 
of community-based specialist behaviour therapy teams, anger management with cognitive 
behaviour therapy and manipulation of social, physical and personal environment 
(nidotherapy).17-19 However, there is insufficient evidence to allow them to be recommended.  
 
Resources  
NHS England: 
 STOMP webpages - https://www.england.nhs.uk/learning-disabilities/improving-
health/stomp/  
 STOMP presentation - https://www.england.nhs.uk/publication/stopping-over-medication-
of-people-with-a-learning-disability-autism-or-both/ 
National Institute for Health and Care Excellence:  
 Guideline (NG11) -  https://www.nice.org.uk/guidance/ng11 
 Medication clinic proforma (shared learning example) - 
https://www.nice.org.uk/Media/Default/sharedlearning/Audit%20Tool%204th%20draft%2
0(4).doc   
 
Conclusion 
Where antipsychotic medication review leads to a decision to reduce or discontinue 
medication, the focus needs to be on improving an individual’s health whilst minimising the 
risk of harm. The risk of continuing medication also needs to be weighed against the 
potential harm it can cause while contributing to a good quality of life. This requires multi-
stakeholder involvement and systems which can review decisions on a regular basis.   For 
services in which there are a number of people who may benefit from medication reduction 
or discontinuation, a priority list based on assessment of complexity, potential or actual 
adverse effects, and the use of restrictive practice, might be useful. Patients who are on very 
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low doses of antipsychotics may be perceived as prime candidates for a ‘quick win’. 
However, as even small doses of medication can have influence on patient presentation, 
due consideration still needs to be given to an appropriate discontinuation and review 
process.  
Withdrawing medication, particularly psychotropic medication, can be challenging and 
requires input from doctors, specialist nurses, speech and language therapists, occupational 
therapists, psychologists, social workers and pharmacists. It is vital to gain the confidence of 
the person with ID and/or autism and their family and carers before embarking on medication 
reduction, and to provide alternative management and support.   
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Pathway Key steps in antipsychotic reduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review medication and consider antipsychotic reduction. 
Discuss antipsychotic reduction with person with ID and 
carers. Explain potential benefits and risks. Aim to reach a 
shared decision. 
Agree a reduction schedule that is flexible and responsive to 
individual response. The process should be informed by 
objective, multi-source behaviour data at baseline and 
during medication change. 
Ensure alternative interventions for behaviour that 
challenges and input of other members of the specialist 
team are available before, during, and after reduction.  
Review reduction regularly and provide carers with a robust 
crisis management plan.  
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Table Good-practice principles for reducing antipsychotic medication used for behaviour that 
challenges in adults with intellectual disability and/or autism 
For all adults who are prescribed antipsychotic drugs for behaviour that challenges  
Conduct regular medication review and consider antipsychotic reduction  
Medication review should form part of the learning disability annual health check, 
completed in primary care. 
In some cases where the person with ID and/or autism is not under review by a specialist, 
antipsychotic reduction may be initiated by a General Practitioner who must be aware of 
sources of specialist support and maintain a low threshold for consultation. 
Before antipsychotic reduction 
Review clinical records to confirm indication for antipsychotic prescription, target 
symptoms, benefits and adverse effects of antipsychotic use, and outcome of any 
previous discontinuation attempts. 
Discuss potential risks and benefits of antipsychotic reduction with patient and carers. Aim 
to understand the ideas, concerns, and expectations of stakeholder groups.  
Support the medication discussion with accessible information and other reasonable 
adjustments. 
A formal best interest decision meeting may be helpful. 
Planning antipsychotic reduction 
Give a clear rationale for antipsychotic reduction. 
Establish current baseline level of behavioural symptoms and adverse drug effects with 
validated measures. 
Avoid major changes to antipsychotic prescription at the same time as significant changes 
in life circumstances (e.g. accommodation, care team, bereavement). 
Ensure the programme of reduction is clear and communicated to all relevant parties (e.g.. 
patient, carers, family, GP, other professionals who may be involved). 
Develop a plan for medication reduction taking into account of patient and carer 
preferences. 
Ensure good support for people with ID and their carers during antipsychotic reduction 
including the availability of alternative methods to manage increases in behaviour that 
challenges. 
During medication reduction 
Review medication reduction and response regularly. 
Aim to collect objective data from different sources and using validated measures. Carers 
can be asked to keep a diary of behaviour before and during antipsychotic reduction.  
Be aware of potential antipsychotic withdrawal effects e.g. dyskinesias. 
Allow flexibility with the pace of medication reduction and remain amenable to halting 
reduction or re-introducing medication. 
Include psychologist or other healthcare professionals in formulating any changes in 
behaviour to avoid falsely misattributing change to medication reduction. 
Continue to monitor physical health (in line with guidelines) while person is prescribed 
antipsychotic drugs. 
After medication reduction 
Continue to review the person and be alert for increase in behaviour that challenges or 
emergence of symptoms of mental illness. 
 
 
 
 
